{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:06:06Z","timestamp":1790478366597,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,10,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: gastroesophageal junction (GEJ)\/cardia and distal gastric adenocarcinomas. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with a histologically proven diagnosis of adenocarcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disease; no prior chemotherapy for advanced or metastatic cancer; Zubrod performance status (PS) of 0 to 1; and adequate renal, hepatic, and hematologic function were treated with erlotinib 150 mg\/d orally. Patient characteristics were median age, GEJ\u201463 years, ST\u201464 years; sex, GEJ\u201484% male and 16% female, ST\u201460 male and 40 female; Zubrod PS, GEJ\u201425 had a PS of 0 and 18 had a PS 1, ST\u201413 had a PS of 0 and 12 had a PS of 1. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Percentage of common toxicities were skin rash, 86% and 72%; fatigue, 51% and 44%; and AST\/ALT elevation, 28% and 28%, respectively for GEJ and ST. There has been one confirmed complete response, three confirmed partial responses (PRs) and one unconfirmed PR for an overall response probability of 9% confirmed (95% CI, 3% to 22%), all occurring in GEJ stratum. No responses were observed in ST stratum. The median survival was 6.7 months in GEJ and 3.5 months in ST stratum. Neither intratumoral EGFR, transforming growth factor\u2013alpha or phosphorylated Akt kinase expression nor plasma proteomic analyses were predictive of clinical outcome. No somatic mutations of the EGFR exons 18, 19, or 21 were detected and there was no gross amplification of EGFR by fluorescence in situ hybridization. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Erlotinib is active in patients with GEJ adenocarcinomas, but appears inactive in gastric cancers. The molecular correlates examined were not predictive of the patient therapeutic response. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.07.1316","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T22:43:12Z","timestamp":1161211392000},"page":"4922-4927","source":"Crossref","is-referenced-by-count":250,"title":["Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127"],"prefix":"10.1200","volume":"24","author":[{"given":"Tomislav","family":"Dragovich","sequence":"first","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"McCoy","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia M.","family":"Fenoglio-Preiser","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline K.","family":"Benedetti","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Baker","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Hackett","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Urba","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken S.","family":"Zaner","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Blanke","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[{"name":"From the University of Arizona Cancer Center, Tucson, AZ; Southwest Oncology Group Statistical Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; University of Michigan, Ann Arbor, MI; Boston University Medical Center, Boston, MA; OR Health & Science University Cancer Institute, Portland, OR; and The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1440"},{"key":"R2","unstructured":"Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 26:2,1999-8,"},{"key":"R3","unstructured":"Dragovich T, Kindler HL: Nonsurgical palliative therapy of advanced gastric cancer, in Posner MC, Vokes EE, Weichselbaum RR, (eds): Cancer of the Upper Gastrointestinal Tract . Hamilton, Ontario, Canada, BC Decker Inc, pp 290,2002-307"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.261"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.376"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20358"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204082"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0790"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.955"},{"key":"R12","unstructured":"Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838,1997-4848,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.075"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.696"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3267"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20357"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Ferry D, Anderson M, Beddows K, et al: Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. J Clin Oncol 22:318s,2004,  (suppl; abstr 4021)","DOI":"10.1200\/jco.2004.22.90140.4021"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Von Groeningen C, Richel D, Giaccone G: Gefitinib phase II study in second-line treatment of advanced esophageal cancer. J Clin Oncol 22:319s,2004,  (suppl; abstr 4022)","DOI":"10.1200\/jco.2004.22.90140.4022"},{"key":"R20","unstructured":"Doi T, Koizumi S, Siena S, et al: Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 22:258,2003,  (abstr 1036)"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4900"},{"key":"R22","unstructured":"Iwata KK, Provoncha K, Gibson N: Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol 21:21a,2002,  (abstr 79)"},{"key":"R23","unstructured":"Heimberger AB, Learn CA, Archer GE, et al: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3496,2002-3502,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2823"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7078"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052698"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.07.1316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:57:15Z","timestamp":1653512235000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.07.1316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,20]]},"references-count":26,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2006,10,20]]}},"alternative-id":["10.1200\/JCO.2006.07.1316"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.07.1316","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,20]]}}}